BR112022025435A2 - Derivados de quinoxalina como fármacos anticâncer - Google Patents

Derivados de quinoxalina como fármacos anticâncer

Info

Publication number
BR112022025435A2
BR112022025435A2 BR112022025435A BR112022025435A BR112022025435A2 BR 112022025435 A2 BR112022025435 A2 BR 112022025435A2 BR 112022025435 A BR112022025435 A BR 112022025435A BR 112022025435 A BR112022025435 A BR 112022025435A BR 112022025435 A2 BR112022025435 A2 BR 112022025435A2
Authority
BR
Brazil
Prior art keywords
quinoxaline derivatives
cancer drugs
drugs
quinoxaline
derivatives
Prior art date
Application number
BR112022025435A
Other languages
English (en)
Portuguese (pt)
Inventor
John Packer Martin
Louis Degorce Sebastien
Wallace Johannes Jeffrey
Mahadeo Hande Sudhir
Ghosh Avipsa
Zheng Xiaolan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112022025435A2 publication Critical patent/BR112022025435A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022025435A 2020-06-25 2021-06-24 Derivados de quinoxalina como fármacos anticâncer BR112022025435A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044095P 2020-06-25 2020-06-25
US202063120351P 2020-12-02 2020-12-02
PCT/EP2021/067304 WO2021260092A1 (en) 2020-06-25 2021-06-24 Quinoxaline derivatives as anti-cancer drugs

Publications (1)

Publication Number Publication Date
BR112022025435A2 true BR112022025435A2 (pt) 2023-01-24

Family

ID=76662494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025435A BR112022025435A2 (pt) 2020-06-25 2021-06-24 Derivados de quinoxalina como fármacos anticâncer

Country Status (22)

Country Link
US (3) US11795158B2 (cg-RX-API-DMAC7.html)
EP (1) EP4172152A1 (cg-RX-API-DMAC7.html)
JP (1) JP7769650B2 (cg-RX-API-DMAC7.html)
KR (1) KR102980562B1 (cg-RX-API-DMAC7.html)
CN (7) CN122059929A (cg-RX-API-DMAC7.html)
AU (1) AU2021295423B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025435A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186996A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003711A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000186A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230024A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000288A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005059A (cg-RX-API-DMAC7.html)
IL (1) IL299123B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022015435A (cg-RX-API-DMAC7.html)
PE (1) PE20231081A1 (cg-RX-API-DMAC7.html)
SA (1) SA522441701B1 (cg-RX-API-DMAC7.html)
TW (1) TWI925847B (cg-RX-API-DMAC7.html)
UA (1) UA130043C2 (cg-RX-API-DMAC7.html)
UY (1) UY39296A (cg-RX-API-DMAC7.html)
WO (1) WO2021260092A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300924B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
US12280049B2 (en) * 2020-08-04 2025-04-22 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer
TW202309025A (zh) 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
AU2022280845A1 (en) 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
JP2024522736A (ja) * 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
AU2022334408A1 (en) 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
WO2023051807A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 双环衍生物parp抑制剂及其用途
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
CA3238572A1 (en) 2021-11-19 2023-05-25 Jing Zhang Selective parp1 inhibitor and application thereof
AU2022422276B2 (en) * 2021-12-21 2025-12-11 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
US20250221987A1 (en) * 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
CA3246093A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. PARP1 INHIBITORS AND THEIR USES
AU2023212785A1 (en) * 2022-01-28 2024-08-15 Xinthera, Inc. Parp1 inhibitors and uses thereof
CN116693501B (zh) * 2022-02-10 2025-12-19 康百达(四川)生物医药科技有限公司 一种喹唑啉酮衍生物及其在医药上的应用
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
PT4497438T (pt) * 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
AU2023275808A1 (en) 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
US20250346573A1 (en) * 2022-06-02 2025-11-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Azaquinolinone derivative, preparation method therefor and use thereof
KR20250023494A (ko) 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
TW202416977A (zh) * 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
US20240174669A1 (en) * 2022-10-06 2024-05-30 Xinthera, Inc. Crystalline forms of a parp1 inhibitor
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
KR20250103773A (ko) 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
CR20250267A (es) 2022-12-06 2026-01-14 Astrazeneca Ab Inhibidores de polq
WO2024255782A1 (zh) 2023-06-14 2024-12-19 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
WO2025067417A1 (zh) 2023-09-28 2025-04-03 成都赜灵生物医药科技有限公司 并内酰胺环类化合物及其用途
WO2025092973A1 (zh) * 2023-11-03 2025-05-08 成都赜灵生物医药科技有限公司 Parp1靶向化合物及其用途
AU2024394093A1 (en) 2023-12-05 2026-06-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
CN120398887A (zh) * 2024-01-31 2025-08-01 西藏海思科制药有限公司 一种双环衍生物parp抑制剂的晶型及其制备方法和应用
KR20250128449A (ko) 2024-02-20 2025-08-28 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
WO2025248119A1 (en) 2024-05-31 2025-12-04 Astrazeneca Ab 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors
TW202608880A (zh) 2024-05-31 2026-03-01 瑞典商阿斯特捷利康公司 Polq抑制劑
KR20260019426A (ko) 2024-08-01 2026-02-10 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
GB2703160A (en) * 2024-12-09 2026-07-15 Duke Street Bio Ltd PARP1 Inhibitor Compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
JP2009196973A (ja) * 2007-09-26 2009-09-03 Santen Pharmaceut Co Ltd キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
WO2014045101A1 (en) * 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
HK1211033A1 (en) * 2012-12-20 2016-05-13 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
PT3312177T (pt) * 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
SA522441701B1 (ar) 2024-08-11
IL299123B1 (en) 2025-12-01
AU2021295423B2 (en) 2024-05-02
US20220009901A1 (en) 2022-01-13
KR102980562B1 (ko) 2026-06-23
US11795158B2 (en) 2023-10-24
CN122036687A (zh) 2026-05-15
AU2021295423A1 (en) 2023-02-16
PE20231081A1 (es) 2023-07-17
CR20230024A (es) 2023-03-01
CN122036686A (zh) 2026-05-15
CN121949283A (zh) 2026-05-01
US12421208B2 (en) 2025-09-23
JP2023532257A (ja) 2023-07-27
TW202218664A (zh) 2022-05-16
CN122010903A (zh) 2026-05-12
CN115768760A (zh) 2023-03-07
IL299123A (en) 2023-02-01
IL299123B2 (en) 2026-04-01
UA130043C2 (uk) 2025-10-22
CL2022003711A1 (es) 2023-06-23
DOP2022000288A (es) 2023-01-15
CN115768760B (zh) 2026-03-27
UY39296A (es) 2021-12-31
EP4172152A1 (en) 2023-05-03
ECSP23005059A (es) 2023-02-28
US20250368615A1 (en) 2025-12-04
WO2021260092A1 (en) 2021-12-30
TWI925847B (zh) 2026-05-21
US20240010631A1 (en) 2024-01-11
ZA202300924B (en) 2024-09-25
CN122059929A (zh) 2026-05-19
KR20230026450A (ko) 2023-02-24
JP7769650B2 (ja) 2025-11-13
CA3186996A1 (en) 2021-12-30
CO2023000186A2 (es) 2023-04-17
MX2022015435A (es) 2023-02-09
CN121873040A (zh) 2026-04-17

Similar Documents

Publication Publication Date Title
CO2023000186A2 (es) Derivados de quinoxalina como fármacos anti-cáncer
BR112022000534A2 (pt) Inibidores de parp1
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
MX2014003334A (es) Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos.
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
ECSP12011716A (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
BR112014019990A8 (pt) Compostos enediinos, seus conjugados e usos e métodos para esses compostos
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
BR112015028876A2 (pt) derivados de perhidroquinoxalina
UY37622A (es) Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas
BR112016001106A8 (pt) Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
BR112015026908A2 (pt) compostos de pirazino[1,2-a]indol, sua preparação e uso em medicamentos
BR112021019589A2 (pt) Derivados de isocromenos como inibidores de fosfoinositídeo 3-cinases
MX375485B (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta
BR112018076014A2 (pt) composições compreendendo timolol e seu uso no tratamento de rosácea por administração tópica

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]